Cargando…

Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker

Triggering receptor expressed on myeloid cells-2 (TREM2) is a transmembrane receptor of the immunoglobulin superfamily and a crucial signaling hub for multiple pathological pathways that mediate immunity. Although increasing evidence supports a vital role for TREM2 in tumorigenesis of some cancers,...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Xin, Wang, Xiaowei, Nie, Kechao, Cheng, Lin, Zhang, Zheyu, Hu, Yang, Peng, Weijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925850/
https://www.ncbi.nlm.nih.gov/pubmed/33679809
http://dx.doi.org/10.3389/fimmu.2021.646523
_version_ 1783659340635308032
author Cheng, Xin
Wang, Xiaowei
Nie, Kechao
Cheng, Lin
Zhang, Zheyu
Hu, Yang
Peng, Weijun
author_facet Cheng, Xin
Wang, Xiaowei
Nie, Kechao
Cheng, Lin
Zhang, Zheyu
Hu, Yang
Peng, Weijun
author_sort Cheng, Xin
collection PubMed
description Triggering receptor expressed on myeloid cells-2 (TREM2) is a transmembrane receptor of the immunoglobulin superfamily and a crucial signaling hub for multiple pathological pathways that mediate immunity. Although increasing evidence supports a vital role for TREM2 in tumorigenesis of some cancers, no systematic pan-cancer analysis of TREM2 is available. Thus, we aimed to explore the prognostic value, and investigate the potential immunological functions, of TREM2 across 33 cancer types. Based on datasets from The Cancer Genome Atlas, and the Cancer Cell Line Encyclopedia, Genotype Tissue-Expression, cBioPortal, and Human Protein Atlas, we employed an array of bioinformatics methods to explore the potential oncogenic roles of TREM2, including analyzing the relationship between TREM2 and prognosis, tumor mutational burden (TMB), microsatellite instability (MSI), DNA methylation, and immune cell infiltration of different tumors. The results show that TREM2 is highly expressed in most cancers, but present at low levels in lung cancer. Further, TREM2 is positively or negatively associated with prognosis in different cancers. Additionally, TREM2 expression was associated with TMB and MSI in 12 cancer types, while in 20 types of cancer, there was a correlation between TREM2 expression and DNA methylation. Six tumors, including breast invasive carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, kidney renal clear cell carcinoma, lung squamous cell carcinoma, skin cutaneous melanoma, and stomach adenocarcinoma, were screened out for further study, which demonstrated that TREM2 gene expression was negatively correlated with infiltration levels of most immune cells, but positively correlated with infiltration levels of M1 and M2 macrophages. Moreover, correlation with TREM2 expression differed according to T cell subtype. Our study reveals that TREM2 can function as a prognostic marker in various malignant tumors because of its role in tumorigenesis and tumor immunity.
format Online
Article
Text
id pubmed-7925850
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79258502021-03-04 Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker Cheng, Xin Wang, Xiaowei Nie, Kechao Cheng, Lin Zhang, Zheyu Hu, Yang Peng, Weijun Front Immunol Immunology Triggering receptor expressed on myeloid cells-2 (TREM2) is a transmembrane receptor of the immunoglobulin superfamily and a crucial signaling hub for multiple pathological pathways that mediate immunity. Although increasing evidence supports a vital role for TREM2 in tumorigenesis of some cancers, no systematic pan-cancer analysis of TREM2 is available. Thus, we aimed to explore the prognostic value, and investigate the potential immunological functions, of TREM2 across 33 cancer types. Based on datasets from The Cancer Genome Atlas, and the Cancer Cell Line Encyclopedia, Genotype Tissue-Expression, cBioPortal, and Human Protein Atlas, we employed an array of bioinformatics methods to explore the potential oncogenic roles of TREM2, including analyzing the relationship between TREM2 and prognosis, tumor mutational burden (TMB), microsatellite instability (MSI), DNA methylation, and immune cell infiltration of different tumors. The results show that TREM2 is highly expressed in most cancers, but present at low levels in lung cancer. Further, TREM2 is positively or negatively associated with prognosis in different cancers. Additionally, TREM2 expression was associated with TMB and MSI in 12 cancer types, while in 20 types of cancer, there was a correlation between TREM2 expression and DNA methylation. Six tumors, including breast invasive carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, kidney renal clear cell carcinoma, lung squamous cell carcinoma, skin cutaneous melanoma, and stomach adenocarcinoma, were screened out for further study, which demonstrated that TREM2 gene expression was negatively correlated with infiltration levels of most immune cells, but positively correlated with infiltration levels of M1 and M2 macrophages. Moreover, correlation with TREM2 expression differed according to T cell subtype. Our study reveals that TREM2 can function as a prognostic marker in various malignant tumors because of its role in tumorigenesis and tumor immunity. Frontiers Media S.A. 2021-02-17 /pmc/articles/PMC7925850/ /pubmed/33679809 http://dx.doi.org/10.3389/fimmu.2021.646523 Text en Copyright © 2021 Cheng, Wang, Nie, Cheng, Zhang, Hu and Peng. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Cheng, Xin
Wang, Xiaowei
Nie, Kechao
Cheng, Lin
Zhang, Zheyu
Hu, Yang
Peng, Weijun
Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker
title Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker
title_full Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker
title_fullStr Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker
title_full_unstemmed Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker
title_short Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker
title_sort systematic pan-cancer analysis identifies trem2 as an immunological and prognostic biomarker
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925850/
https://www.ncbi.nlm.nih.gov/pubmed/33679809
http://dx.doi.org/10.3389/fimmu.2021.646523
work_keys_str_mv AT chengxin systematicpancanceranalysisidentifiestrem2asanimmunologicalandprognosticbiomarker
AT wangxiaowei systematicpancanceranalysisidentifiestrem2asanimmunologicalandprognosticbiomarker
AT niekechao systematicpancanceranalysisidentifiestrem2asanimmunologicalandprognosticbiomarker
AT chenglin systematicpancanceranalysisidentifiestrem2asanimmunologicalandprognosticbiomarker
AT zhangzheyu systematicpancanceranalysisidentifiestrem2asanimmunologicalandprognosticbiomarker
AT huyang systematicpancanceranalysisidentifiestrem2asanimmunologicalandprognosticbiomarker
AT pengweijun systematicpancanceranalysisidentifiestrem2asanimmunologicalandprognosticbiomarker